1-13 of 13
Henry N. Ginsberg
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Relationship Between Time-Varying Achieved HbA1c and Risk of Coronary Events Depends on Haptoglobin Phenotype Among White and Black ACCORD Participants

Free
Leah E. Cahill, Rachel A. Warren, Allie S. Carew, Andrew P. Levy, Henry N. Ginsberg, John Sapp, Orit Lache, Eric B. Rimm
Journal: Diabetes Care
Diabetes Care 2023;46(11):1941–1948
https://doi.org/10.2337/dc23-0760
Published: 28 August 2023
View articletitled, The Relationship Between Time-Varying Achieved HbA1c and Risk of Coronary Events Depends on Haptoglobin Phenotype Among White and Black ACCORD Participants
Open the PDF for The Relationship Between Time-Varying Achieved HbA1c and Risk of Coronary Events Depends on Haptoglobin Phenotype Among White and Black ACCORD Participants in another window
Journal Articles

Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin Therapy

Free
Henry N. Ginsberg, Neil J. Hounslow, Yusuke Senko, Hideki Suganami, Pawel Bogdanski, Richard Ceska, Akos Kalina, Roman A. Libis, Tatiana V. Supryadkina, G. Kees Hovingh
Journal: Diabetes Care
Diabetes Care 2022;45(4):898–908
https://doi.org/10.2337/dc21-1288
Published: 25 March 2022
View articletitled, Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin Therapy
Open the PDF for Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin Therapy in another window
Journal Articles

Effect of Fenofibrate Therapy on Laser Treatment for Diabetic Retinopathy: A Meta-Analysis of Randomized Controlled Trials

Free
David Preiss, Enti Spata, Rury R. Holman, Ruth L. Coleman, Laura Lovato, Henry N. Ginsberg, Jane Armitage
Journal: Diabetes Care
Diabetes Care 2022;45(1):e1–e2
https://doi.org/10.2337/dc21-1439
Published: 28 December 2021
View articletitled, Effect of Fenofibrate Therapy on Laser Treatment for Diabetic Retinopathy: A Meta-Analysis of Randomized Controlled Trials
Open the PDF for Effect of Fenofibrate Therapy on Laser Treatment for Diabetic Retinopathy: A Meta-Analysis of Randomized Controlled Trials in another window
Journal Articles

Haptoglobin Phenotype Modifies the Effect of Fenofibrate on Risk of Coronary Event: ACCORD Lipid Trial

Free
Rachel A. Warren, Allie S. Carew, Pantelis Andreou, Christine Herman, Andrew P. Levy, Henry N. Ginsberg, John Sapp, Eric B. Rimm, Susan Kirkland, Leah E. Cahill
Journal: Diabetes Care
Diabetes Care 2022;45(1):241–250
https://doi.org/10.2337/dc21-1429
Published: 16 November 2021
View articletitled, Haptoglobin Phenotype Modifies the Effect of Fenofibrate on Risk of Coronary Event: ACCORD Lipid Trial
Open the PDF for Haptoglobin Phenotype Modifies the Effect of Fenofibrate on Risk of Coronary Event: ACCORD Lipid Trial in another window
Journal Articles

Predicting the Effect of Fenofibrate on Cardiovascular Risk for Individual Patients With Type 2 Diabetes

Free
Charlotte Koopal, Frank L.J. Visseren, Jan Westerink, Yolanda van der Graaf, Henry N. Ginsberg, Anthony C. Keech
Journal: Diabetes Care
Diabetes Care 2018;41(6):1244–1250
https://doi.org/10.2337/dc17-0968
Published: 22 February 2018
View articletitled, Predicting the Effect of Fenofibrate on Cardiovascular Risk for Individual Patients With Type 2 Diabetes
Open the PDF for Predicting the Effect of Fenofibrate on Cardiovascular Risk for Individual Patients With Type 2 Diabetes in another window
Includes: Supplementary data
Journal Articles

Gerald M. Reaven, MD: Demonstration of the Central Role of Insulin Resistance in Type 2 Diabetes and Cardiovascular Disease

Open Access
Fredric B. Kraemer, Henry N. Ginsberg
Journal: Diabetes Care
Diabetes Care 2014;37(5):1178–1181
https://doi.org/10.2337/dc13-2668
Published: 10 April 2014
View articletitled, Gerald M. Reaven, MD: Demonstration of the Central Role of Insulin Resistance in Type 2 Diabetes and Cardiovascular Disease
Open the PDF for Gerald M. Reaven, MD: Demonstration of the Central Role of Insulin Resistance in Type 2 Diabetes and Cardiovascular Disease in another window
Journal Articles

Paradoxical Reduction in HDL-C With Fenofibrate and Thiazolidinedione Therapy in Type 2 Diabetes: The ACCORD Lipid Trial

Open Access
Peter E. Linz, Laura C. Lovato, Robert P. Byington, Patrick J. O’Connor, Lawrence A. Leiter, Daniel Weiss, Rex W. Force, John R. Crouse, Faramarz Ismail-Beigi, Debra L. Simmons, Vasilios Papademetriou, Henry N. Ginsberg, Marshall B. Elam
Journal: Diabetes Care
Diabetes Care 2014;37(3):686–693
https://doi.org/10.2337/dc13-0790
Published: 11 February 2014
View articletitled, Paradoxical Reduction in HDL-C With Fenofibrate and Thiazolidinedione Therapy in Type 2 Diabetes: The ACCORD Lipid Trial
Open the PDF for Paradoxical Reduction in HDL-C With Fenofibrate and Thiazolidinedione Therapy in Type 2 Diabetes: The ACCORD Lipid Trial in another window
Includes: Supplementary data
Journal Articles

Effects of Randomization to Intensive Glucose Control on Adverse Events, Cardiovascular Disease, and Mortality in Older Versus Younger Adults in the ACCORD Trial

Open Access
Michael E. Miller, Jeff D. Williamson, Hertzel C. Gerstein, Robert P. Byington, William C. Cushman, Henry N. Ginsberg, Walter T. Ambrosius, Laura Lovato, William B. Applegate, for the ACCORD Investigators
Journal: Diabetes Care
Diabetes Care 2014;37(3):634–643
https://doi.org/10.2337/dc13-1545
Published: 11 February 2014
View articletitled, Effects of Randomization to Intensive Glucose Control on Adverse Events, Cardiovascular Disease, and Mortality in Older Versus Younger Adults in the ACCORD Trial
Open the PDF for Effects of Randomization to Intensive Glucose Control on Adverse Events, Cardiovascular Disease, and Mortality in Older Versus Younger Adults in the ACCORD Trial in another window
Includes: Supplementary data
Journal Articles

Effect of Combination Therapy With Fenofibrate and Simvastatin on Postprandial Lipemia in the ACCORD Lipid Trial

Open Access
Gissette Reyes-Soffer, MD, Colleen I. Ngai, BS, Laura Lovato, MS, Wahida Karmally, DRPH, Rajasekhar Ramakrishnan, SCD, Stephen Holleran, BS, Henry N. Ginsberg, MD
Journal: Diabetes Care
Diabetes Care 2013;36(2):422–428
https://doi.org/10.2337/dc11-2556
Published: 17 January 2013
View articletitled, Effect of Combination Therapy With Fenofibrate and Simvastatin on Postprandial Lipemia in the ACCORD Lipid Trial
Open the PDF for Effect of Combination Therapy With Fenofibrate and Simvastatin on Postprandial Lipemia in the ACCORD Lipid Trial in another window
Journal Articles

Reversibility of Fenofibrate Therapy–Induced Renal Function Impairment in ACCORD Type 2 Diabetic Participants

Open Access
Josyf C. Mychaleckyj, DPHIL, Timothy Craven, MS, Uma Nayak, PHD, John Buse, MD, John R. Crouse, MD, Marshall Elam, MD, Kent Kirchner, MD, Daniel Lorber, MD, Santica Marcovina, PHD, William Sivitz, MD, JoAnn Sperl-Hillen, MD, Denise E. Bonds, MD, Henry N. Ginsberg, MD
Journal: Diabetes Care
Diabetes Care 2012;35(5):1008–1014
https://doi.org/10.2337/dc11-1811
Published: 11 April 2012
View articletitled, Reversibility of Fenofibrate Therapy–Induced Renal Function Impairment in ACCORD Type 2 Diabetic Participants
Open the PDF for Reversibility of Fenofibrate Therapy–Induced Renal Function Impairment in ACCORD Type 2 Diabetic Participants in another window
Includes: Supplementary data
Journal Articles

The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Lipid Trial: What we learn from subgroup analyses

Open Access
Henry N. Ginsberg, MD
Journal: Diabetes Care
Diabetes Care 2011;34(Supplement_2):S107–S108
https://doi.org/10.2337/dc11-s203
Published: 22 April 2011
View articletitled, The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Lipid Trial: What we learn from subgroup analyses
Open the PDF for The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Lipid Trial: What we learn from subgroup analyses in another window
Journal Articles

Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A scientific statement from the American Heart Association and the American Diabetes Association

Free
John B. Buse, MD, PHD, Henry N. Ginsberg, MD, George L. Bakris, MD, Nathaniel G. Clark, MD, MS, RD, Fernando Costa, MD, Robert Eckel, MD, Vivian Fonseca, MD, Hertzel C. Gerstein, MD, MSC, FRCPC, Scott Grundy, MD, PHD, Richard W. Nesto, MD, Michael P. Pignone, MD, MPH, Jorge Plutzky, MD, Daniel Porte, MD, Rita Redberg, MD, Kimberly F. Stitzel, MS, RD, Neil J. Stone, MD
Journal: Diabetes Care
Diabetes Care 2007;30(1):162–172
https://doi.org/10.2337/dc07-9917
Published: 01 January 2007
View articletitled, Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A scientific statement from the American Heart Association and the American Diabetes Association
Open the PDF for Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A scientific statement from the American Heart Association and the American Diabetes Association in another window
Journal Articles

Lipoprotein Physiology in Nondiabetic and Diabetic States: Relationship to Atherogenesis

Free
Henry N Ginsberg, MD
Journal: Diabetes Care
Diabetes Care 1991;14(9):839–855
https://doi.org/10.2337/diacare.14.9.839
Published: 01 September 1991
View articletitled, Lipoprotein Physiology in Nondiabetic and Diabetic States: Relationship to Atherogenesis
Open the PDF for Lipoprotein Physiology in Nondiabetic and Diabetic States: Relationship to Atherogenesis in another window